Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,035 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,952 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03600363 | A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients | unknown | Phase 2 | 250 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT03930043 | A Metagenome-wide Association Study of Gut Microbiota in Gastrointestinal Non-Hodgkin's Lymphoma Patients | unknown | — | 160 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT04096690 |
| Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma |
| unknown |
| Phase 2 |
| 22 |
| Ruijin HospitalOTHER |
| 1 |
| Mar 11, 2020 |
| clinicaltrials |
| NCT02533700 | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | unknown | Phase 2 | 106 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00276783 | Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases | unknown | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT04296786 | Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study | unknown | Phase 2 | 52 | Peking Union Medical College HospitalOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT04295018 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03385096 | Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03051841 | CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT03150316 | CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | unknown | Phase 1 | 18 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Feb 24, 2020 | clinicaltrials |
| NCT04226989 | A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy | unknown | Early Phase 1 | 72 | He HuangOTHER | 1 | Feb 21, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04264039 | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03633045 | Observational Study of Ibrutinib Use in CLL | unknown | — | 70 | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of HealthOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04260490 | Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.(MYELODOM) | unknown | — | 600 | Centre Hospitalier Universitaire de la GuadeloupeOTHER | 2 | Feb 7, 2020 | clinicaltrials |
| NCT02364050 | Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM | unknown | — | 1,300 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT01953770 | Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008(ALL-MB 2008) | unknown | N/A | 3,000 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 3 | Feb 5, 2020 | clinicaltrials |
| NCT02577783 | PDD vs PAD to Treat Initially Diagnosed MM | unknown | Phase 4 | 64 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03390387 | Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)(ALL-MB 2015) | unknown | N/A | 4,000 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 5 | Feb 5, 2020 | clinicaltrials |
| NCT04109872 | Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results. | unknown | — | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04237168 | Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL) | unknown | — | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT02918747 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | unknown | Phase 2 | 100 | Hunan Cancer HospitalOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT02267915 | Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT(MAN2) | unknown | Phase 2 | 36 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04206943 | Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL(ISIKOK-19) | unknown | Phase 1 / Phase 2 | 24 | Acibadem UniversityOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04237428 | CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma | unknown | N/A | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT04239170 | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 84 | Peking UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03015922 | Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma(MUKeleven) | unknown | Phase 1 | 4 | University of LeedsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03847727 | Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia | unknown | — | 112 | Pirogov Russian National Research Medical UniversityOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02605460 | Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission | unknown | Phase 2 | 20 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03339700 | Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia | unknown | Phase 2 | 15 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04154709 | CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 15 | Kai Lin Xu; Jun Nian ZhengOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04228393 | The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China | unknown | Phase 2 / Phase 3 | 82 | Wei ZhaoOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03977103 | Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT | unknown | Phase 2 | 80 | University Of PerugiaOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02788084 | Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow | unknown | — | 80 | Alberta Health Services, CalgaryOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04221620 | Effectiveness of EEG Neurofeedback in Pediatric Occupational Therapy to Improve Executive Functioning | unknown | N/A | 30 | Northern Arizona UniversityOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT00505999 | Etiology of Multiple Myeloma: A Case-Control Study | unknown | — | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04212858 | Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma | unknown | N/A | 100 | Assiut UniversityOTHER | 0 | Dec 30, 2019 | clinicaltrials |
| NCT03436342 | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT04163575 | Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL | unknown | Phase 1 / Phase 2 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 23, 2019 | clinicaltrials |
| NCT02856048 | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer(PRESOV) | unknown | Phase 2 / Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02186574 | Tenofovir to Prevent HBV Reactivation | unknown | Phase 3 | 184 | University Health Network, TorontoOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT04196205 | Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04023916 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 11, 2019 | clinicaltrials |
| NCT04194931 | Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 20 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT03720496 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy | unknown | Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Mar 11, 2020source: clinicaltrials